ERYTHROMYCN IN EARLY SYPHILIS*

BY

W. L. FERANDO
V.D. Clinic, Colombo, Ceylon

Keller and Morton (1953) first discovered the treponemical properties of erythromycin and Turner and Schaeffer (1954) showed that erythromycin came second to penicillin as the most active antibiotic against Treponema pallidum. Kolmer and Rule (1956) attributed treponemical properties to erythromycin, but obtained superior results with several other antibiotics. Alexander and Schoch (1954) treated four cases of early syphilis with erythromycin and observed the rapid disappearance of Treponema pallidum from the lesions, noting that the lesions healed as promptly as with other drugs. Montero (1956) treated 27 cases of early syphilis with erythromycin (9–12 g.) with satisfactory results, and Montgomery and Knox (1959) obtained encouraging results in forty cases using a similar dosage. Gertler (1961) treated twelve patients with early syphilis using 1–1–6 g. of erythromycin daily for 15–20 days (follow-up period 7 months) and concluded that erythromycin had a place in the treatment of those allergic to penicillin. Montgomery, Knox, Sciple, and Vanderstoep (1961) treated 148 cases of dark-field positive syphilis with different schedules of erythromycin, and concluded that 20 g. spread over 10 days might prove satisfactory, but that 10 g. over 10 days was not adequate and 9–10 g. over 3–5 days was unsatisfactory. Greaves (1961) treated 29 cases of early syphilis and seventeen completed treatment and follow-up with a cerebrospinal fluid examination. He concluded that the results obtained with erythromycin were not comparable to those obtained with the usual dose of penicillin, but he used only a total dose of 10 g. in an 8-day course of treatment. Moore, Vander Stoep, Knox and Montgomery (1962) treated 130 dark-field positive cases of primary and secondary syphilis using three schedules of treatment, and found good results in those given 500 mg. three times a day for 10 days and 500 mg. 6-hrly for 10 days, but in those given 250 mg. 6-hrly for 10 days the results were unsatisfactory. Wojtkiewiczowa and Toruniowa (1965) treated 58 cases of early syphilis with 2 g. daily for 10 days and observed that erythromycin could be recommended in early syphilis as a substitute for penicillin in penicillin-sensitized patients. Lucas and Price (1967), in a co-operative evaluation of treatment for early syphilis, concluded that a total dose of 20 g. erythromycin was not adequate for the treatment of early syphilis but that a body-weight analysis suggested that a 30 g. dosage would be effective. The dosage of erythromycin recommended by the U.S. Public Health Service (USPHS, 1960) was 20–30 g. given over 10 to 15 days.

Material and Methods

Erythromycin is the drug of choice at this clinic for the treatment of early syphilis when patients are sensitive to penicillin. 34 patients have been treated, of which six were cases of sero-negative primary syphilis, fourteen of sero-positive primary syphilis, and thirteen of secondary syphilis; there was one case of early latent infection.

All patients at this clinic are given a skin test for penicillin sensitivity before penicillin is given and in 31 of the 34 cases there had been a positive reaction, while in three a sensitivity reaction had developed after the first injection of PAM (procaine penicillin with 2 per cent. aluminium monostearate). The dose of erythromycin given to these patients (whose average weight was about 120 lb.) was 500 mg. 6-hrly for 10 days, i.e. a total dosage of 20 g. Six of these patients had only 8 days’ treatment.

Usually sufficient capsules are given to the patient to last 2 to 3 days, after which he should re-attend regularly to be issued with a supply of the drug for 2 to 3 day periods until the treatment is completed. After the lesions have healed, he is followed at monthly intervals, with a clinical examination and a VDRL blood test. Tests of the cerebrospinal fluid are carried out after one year.

*Received for publication January 15, 1969.
ERYTHROMYCIN IN EARLY SYPHILIS

Results

It was observed that in almost all cases the lesions had healed before the treatment was completed. Only one patient, a case of sero-positive primary syphilis, complained of diarrhoea with blood and mucus after the treatment was over; his lesions had all healed by this time.

The periods of follow-up of the 34 patients are tabulated below.

All six cases of sero-negative primary syphilis continued to be sero-negative after treatment. One case became sero-positive at the second month, but became sero-negative at the next month and continued so. Of the fourteen sero-positive cases, ten became sero-negative after treatment: four at one month and one each after 2, 3, 4, 5, 8, and 9 months respectively. The remaining four were still sero-positive at the end of the follow-up period of 2, 14, 16, and 18 months respectively.

Of the thirteen cases of secondary syphilis, seven became sero-negative after treatment at 3 months (2 cases), and one each at 4, 5, 9, 11, and 18 months respectively. Six were sero-positive at the end of the follow-up period of 1 month, 3, 7, 8, 10, and 13 months.

The only case of early latent syphilis was positive at the end of the follow-up period of 4 months after treatment.

Cerebrospinal Fluid Examination

Seven of these patients had a cerebrospinal fluid examination after treatment; they comprised one case of sero-negative and two of sero-positive primary syphilis and four cases of secondary syphilis. Lumbar punctures were performed: 2 years after treatment in four cases, 21 months after treatment in one case, and 16 months after treatment in two. The cerebrospinal fluid was normal in all cases. The examination included a VDRL test, and the VDRL result in the blood of these patients was negative at the time of the lumbar puncture in all these cases.

Summary

34 patients with early syphilis treated with erythromycin 500 mg. 6-hrly for 10 days, i.e. a total of 20 g. (the average weight of the patients being 120 lb.), were followed up for varying periods—four for over 24 months, seventeen for over 12 months, 22 for over 7 months, 29 for over 3 months, etc. Of these, seven underwent cerebrospinal fluid examination at least 16 months after treatment, with normal results in all cases. There was no evidence of relapse in any of these cases. The results were found to be quite satisfactory and encouraging.

REFERENCES


L’Érythromycine dans la syphilis récente

RÉSUMÉ

34 malades (poids moyen: 54 kg.) atteints de syphilis récente et traités par l’érythromycine—500 mg. toutes les 6 h. pendant 10 jours, soit un total de 20 g.—furent suivis des temps variés: 4 plus de 24 mois; 17 plus de 12 mois; 22 plus de 7 mois; 29 plus de 3 mois, etc. Parmi eux, sept ont eu, au moins 16 mois après le traitement, un examen du liquide céphalorachidien avec des résultats normaux dans tous les cas. Les résultats sont considérés comme tout-à-fait satisfaisants et encourageants.

<table>
<thead>
<tr>
<th>Months</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>34</td>
<td>30</td>
<td>29</td>
<td>26</td>
<td>22</td>
<td>22</td>
<td>22</td>
<td>22</td>
<td>21</td>
<td>21</td>
<td>17</td>
<td>17</td>
<td>15</td>
<td>13</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Months</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>20</td>
<td>21</td>
<td>22</td>
<td>23</td>
<td>24 and over</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of patients</td>
<td>10</td>
<td>9</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Erythromycin in early syphilis.

W L Fernando

*Br J Vener Dis* 1969 45: 200-201
doi: 10.1136/sti.45.3.200

Updated information and services can be found at:
http://sti.bmj.com/content/45/3/200.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/